Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076298918> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2076298918 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCIn our recent research activities, we identified a group of novel candidate tumor markers for prevalent cancers. Tissue microarray (TMA) representing breast, lung colon ovary and prostate cancers were analyzed by a high-throughput immunohistochemistry screening using of a library of 1600 mouse antibodies raised against membrane-associated and secreted human proteins for which little is known in the scientific literature. 89 proteins were found over-expressed in one or more of the five tumors under analysis. IHC analysis on TMA representing tissues from 50 patients per each of the five cancers allowed to select a group of 20 potential markers over-expressed in cancer with frequencies ranging from 20 to 96%, with concomitant marginal expression in normal tissues. With the aim at validating these proteins as novel markers for patient stratification, prognosis and response to therapy, highly specific monoclonal antibodies (mAbs) have been generated against them. Currently, mAbs against 4 markers able to selectively detect their target proteins in cancers by IHC have been already identified (positivity ranging from 15 up to 94%, and showing membranous or intracellular staining). The target proteins of these mAbs include:1) a scavenger receptor protein; 2) a putative metallo-protease, 3) a lectin-binding protein involved in the innate immune response, 4) a cadherin- homologous protein. The mAb clinical value is being examines using high-density TMA representing patients with known history and follow-up for breast (1553 patients), colon (1420 patients), lung (1527 patients), ovary (112 patients) and prostate (553 patients) cancers have been generated. The patient cohorts have been collected at the biobank of the institute for Pathology of Basel to select pools of prognostic/predictive monoclonal antibodies capable of discriminating i) patients with favorable or adverse prognosis, and ii) patients that respond/do not respond to specific therapeutic interventions. Available data indicated that these antibodies, alone and in combinations, show significant association with specific clinical features (formation of metastasis, progression-free survival, survival time). Interesting, some of available antibodies show therapeutic activity in preclinical cancer models. These antibodies are able to bind the surface of cancer cells in vitro and in vivo. Avalable data show that one mAb targeting the cadherin-like protein inhibits tumor growth in athymic nude mice bearing HCT15 and HT29 colon cancer xenograft models. Overall, these novel markers and their specific monoclonal antibodies could offer new opportunities for cancer diagnosis and treatment.Citation Format: Renata Maria Grifantini, Piero Pileri, Matteo Parri, Alberto Grandi, Susanna Campagnoli, Renzo Nogarotto, Elena De Camilli, Serenella Eppenberger, Luigi Terracciano, Giuseppe Viale, Guido Grandi, Paolo Sarmientos. Monoclonal antibodies against novel tumor markers for cancer diagnosis and treatment . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2857. doi:10.1158/1538-7445.AM2013-2857" @default.
- W2076298918 created "2016-06-24" @default.
- W2076298918 creator A5008388787 @default.
- W2076298918 creator A5008971324 @default.
- W2076298918 creator A5011419880 @default.
- W2076298918 creator A5015590466 @default.
- W2076298918 creator A5016860319 @default.
- W2076298918 creator A5019285995 @default.
- W2076298918 creator A5040497184 @default.
- W2076298918 creator A5048639797 @default.
- W2076298918 creator A5063146246 @default.
- W2076298918 creator A5066186749 @default.
- W2076298918 creator A5077689990 @default.
- W2076298918 creator A5088697304 @default.
- W2076298918 date "2013-04-15" @default.
- W2076298918 modified "2023-09-27" @default.
- W2076298918 title "Abstract 2857: Monoclonal antibodies against novel tumor markers for cancer diagnosis and treatment ." @default.
- W2076298918 doi "https://doi.org/10.1158/1538-7445.am2013-2857" @default.
- W2076298918 hasPublicationYear "2013" @default.
- W2076298918 type Work @default.
- W2076298918 sameAs 2076298918 @default.
- W2076298918 citedByCount "0" @default.
- W2076298918 crossrefType "proceedings-article" @default.
- W2076298918 hasAuthorship W2076298918A5008388787 @default.
- W2076298918 hasAuthorship W2076298918A5008971324 @default.
- W2076298918 hasAuthorship W2076298918A5011419880 @default.
- W2076298918 hasAuthorship W2076298918A5015590466 @default.
- W2076298918 hasAuthorship W2076298918A5016860319 @default.
- W2076298918 hasAuthorship W2076298918A5019285995 @default.
- W2076298918 hasAuthorship W2076298918A5040497184 @default.
- W2076298918 hasAuthorship W2076298918A5048639797 @default.
- W2076298918 hasAuthorship W2076298918A5063146246 @default.
- W2076298918 hasAuthorship W2076298918A5066186749 @default.
- W2076298918 hasAuthorship W2076298918A5077689990 @default.
- W2076298918 hasAuthorship W2076298918A5088697304 @default.
- W2076298918 hasConcept C121608353 @default.
- W2076298918 hasConcept C126322002 @default.
- W2076298918 hasConcept C142724271 @default.
- W2076298918 hasConcept C159654299 @default.
- W2076298918 hasConcept C193270364 @default.
- W2076298918 hasConcept C203014093 @default.
- W2076298918 hasConcept C204232928 @default.
- W2076298918 hasConcept C2780192828 @default.
- W2076298918 hasConcept C502942594 @default.
- W2076298918 hasConcept C530470458 @default.
- W2076298918 hasConcept C542903549 @default.
- W2076298918 hasConcept C71924100 @default.
- W2076298918 hasConcept C86803240 @default.
- W2076298918 hasConceptScore W2076298918C121608353 @default.
- W2076298918 hasConceptScore W2076298918C126322002 @default.
- W2076298918 hasConceptScore W2076298918C142724271 @default.
- W2076298918 hasConceptScore W2076298918C159654299 @default.
- W2076298918 hasConceptScore W2076298918C193270364 @default.
- W2076298918 hasConceptScore W2076298918C203014093 @default.
- W2076298918 hasConceptScore W2076298918C204232928 @default.
- W2076298918 hasConceptScore W2076298918C2780192828 @default.
- W2076298918 hasConceptScore W2076298918C502942594 @default.
- W2076298918 hasConceptScore W2076298918C530470458 @default.
- W2076298918 hasConceptScore W2076298918C542903549 @default.
- W2076298918 hasConceptScore W2076298918C71924100 @default.
- W2076298918 hasConceptScore W2076298918C86803240 @default.
- W2076298918 hasLocation W20762989181 @default.
- W2076298918 hasOpenAccess W2076298918 @default.
- W2076298918 hasPrimaryLocation W20762989181 @default.
- W2076298918 hasRelatedWork W1508933275 @default.
- W2076298918 hasRelatedWork W1550064565 @default.
- W2076298918 hasRelatedWork W1972311005 @default.
- W2076298918 hasRelatedWork W1984201622 @default.
- W2076298918 hasRelatedWork W2001990091 @default.
- W2076298918 hasRelatedWork W2003631890 @default.
- W2076298918 hasRelatedWork W2010203523 @default.
- W2076298918 hasRelatedWork W2018893491 @default.
- W2076298918 hasRelatedWork W2031382301 @default.
- W2076298918 hasRelatedWork W2087829666 @default.
- W2076298918 hasRelatedWork W2312997393 @default.
- W2076298918 hasRelatedWork W2328055375 @default.
- W2076298918 hasRelatedWork W2563569306 @default.
- W2076298918 hasRelatedWork W2565288442 @default.
- W2076298918 hasRelatedWork W2797028915 @default.
- W2076298918 hasRelatedWork W2914815791 @default.
- W2076298918 hasRelatedWork W2918057456 @default.
- W2076298918 hasRelatedWork W3178037506 @default.
- W2076298918 hasRelatedWork W389528255 @default.
- W2076298918 hasRelatedWork W573954509 @default.
- W2076298918 isParatext "false" @default.
- W2076298918 isRetracted "false" @default.
- W2076298918 magId "2076298918" @default.
- W2076298918 workType "article" @default.